Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene

Gene therapy has promising applications in ovarian cancer therapy. Blocking the function of the survivin protein could lead to the growth inhibition of cancer cells. Herein, we used degradable heparin–polyethyleneimine (HPEI) nanoparticles to deliver a dominant-negative human survivin T34A (hs-T34A) gene to treat ovarian cancer. HPEI nanoparticles were characterized and were found to have a dynamic diameter of 66±4.5 nm and a zeta potential of 27.1±1.87 mV. The constructed hs-T34A gene expression plasmid could be effectively delivered into SKOV3 ovarian carcinoma cells by HPEI nanoparticles with low cytotoxicity. Intraperitoneal administration of HPEI/hs-T34A complexes could markedly inhibit tumor growth in a mouse xenograft model of SKOV3 human ovarian cancer. Moreover, according to our results, apparent apoptosis of cancer cells was observed both in vitro and in vivo. Taken together, the prepared HPEI/hs-T34A formulation showed potential applications in ovarian cancer gene therapy.

[1]  S. Priori,et al.  Gene therapy to treat cardiac arrhythmias , 2015, Nature Reviews Cardiology.

[2]  Somin Lee,et al.  Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  N. Boulis,et al.  Gene therapy for neurodegenerative diseases. , 2015, Trends in molecular medicine.

[4]  S. Davis,et al.  Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer , 2015, Clinical Cancer Research.

[5]  Quanshun Li,et al.  N-Isopropylacrylamide-modified polyethylenimine-mediated p53 gene delivery to prevent the proliferation of cancer cells. , 2015, Colloids and surfaces. B, Biointerfaces.

[6]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[7]  Murali Ramamoorth,et al.  Non viral vectors in gene therapy- an overview. , 2015, Journal of clinical and diagnostic research : JCDR.

[8]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[9]  K. Riabowol,et al.  Survivin as a Preferential Target for Cancer Therapy , 2014, International journal of molecular sciences.

[10]  P. Schlag,et al.  Current status of gene therapy for cancer , 2013, Current opinion in oncology.

[11]  P. Leboulch.  Gene therapy: Primed for take-off , 2013, Nature.

[12]  Jie Zhang,et al.  Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. , 2013, Cancer cell.

[13]  Jo Wixon,et al.  Gene therapy clinical trials worldwide to 2012 – an update , 2013, The journal of gene medicine.

[14]  S. Kaye,et al.  New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential , 2013, Clinical Cancer Research.

[15]  Rasika M. Samarasinghe,et al.  Nanotechnology based platforms for survivin targeted drug discovery , 2012, Expert opinion on drug discovery.

[16]  P. Chu,et al.  Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly. , 2012, Biomaterials.

[17]  Yuquan Wei,et al.  Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels. , 2012, Oncology reports.

[18]  Mauro Giacca,et al.  Virus-mediated gene delivery for human gene therapy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Yuquan Wei,et al.  Efficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin-polyethyleneimine nanogels. , 2011, Oncology reports.

[20]  A. Sood,et al.  Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer , 2011, Clinical Cancer Research.

[21]  A. Yamaguchi,et al.  Phase I clinical trial of survivin‐derived peptide vaccine therapy for patients with advanced or recurrent oral cancer , 2011, Cancer science.

[22]  N. Wall,et al.  Survivin-T34A: molecular mechanism and therapeutic potential , 2010, OncoTargets and therapy.

[23]  Yuquan Wei,et al.  Efficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimine. , 2010, ACS nano.

[24]  Yu‐quan Wei,et al.  Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[25]  Dohyung Lim,et al.  Heparin-coated gold nanoparticles for liver-specific CT imaging. , 2009, Chemistry.

[26]  G. Giaccone,et al.  Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Meredith A Mintzer,et al.  Nonviral vectors for gene delivery. , 2009, Chemical reviews.

[28]  Alain C. Mita,et al.  Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics , 2008, Clinical Cancer Research.

[29]  D. Altieri.  Survivin, cancer networks and pathway-directed drug discovery , 2008, Nature Reviews Cancer.

[30]  W. Mann,et al.  Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. , 2007, Cancer research.

[31]  A. Göpferich,et al.  Polyethylenimine-based non-viral gene delivery systems. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[32]  I. McNeish,et al.  Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy , 2003, Oncogene.

[33]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[34]  D. Fischer,et al.  Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[35]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[36]  J. Pober,et al.  Control of apoptosis during angiogenesis by survivin expression in endothelial cells. , 2000, The American journal of pathology.

[37]  A. Kabanov,et al.  Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents , 2000, Gene Therapy.

[38]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[39]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[40]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[41]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.